| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
Potassium 2-hydroxy-2-methylsuccinate does not have a specific pharmacological target as it is an endogenous metabolite. As a metabolite, it is involved in metabolic pathways, possibly related to the tricarboxylic acid (TCA) cycle or amino acid metabolism. Its "target" in research is the metabolic pathways in which it participates.
|
|---|---|
| ln Vitro |
In vitro activity of Potassium 2-hydroxy-2-methylsuccinate is not evaluated as a bioactive compound with pharmacological effects. Its utility lies in its role as a research reagent to explore metabolic pathways, enzyme interactions, and organic synthesis processes. Its "activity" is reflected in its chemical properties as a metabolite.
|
| ln Vivo |
In vivo, Potassium 2-hydroxy-2-methylsuccinate is an endogenous metabolite. It is not a therapeutic agent but is studied in the context of metabolism. Its levels in biological samples may reflect metabolic activity or alterations in disease states.
|
| Enzyme Assay |
In vitro enzyme assays with Potassium 2-hydroxy-2-methylsuccinate typically involve studying enzymes that recognize or metabolize hydroxy acids or succinate derivatives. The compound can be used as a substrate or inhibitor in assays to characterize the activity of these enzymes. Standard assays involve incubating with enzyme preparations and analyzing products by chromatographic methods.
|
| Cell Assay |
Potassium 2-hydroxy-2-methylsuccinate is not typically used in cell culture experiments as a bioactive compound. However, it may be employed in studies investigating metabolic pathways or as a supplement in defined media. Its primary use is as a research reagent for exploring metabolic pathways and enzyme interactions.
|
| Animal Protocol |
In vivo animal experiments with Potassium 2-hydroxy-2-methylsuccinate are not commonly performed as the compound is an endogenous metabolite. If used, it would be to study metabolic pathways or to validate analytical methods for measuring metabolites in biological samples. Its primary significance is in research as a reference standard and reagent.
|
| ADME/Pharmacokinetics |
The pharmacokinetic (PK) properties of Potassium 2-hydroxy-2-methylsuccinate are not characterized as the compound is a metabolite rather than a drug. As a small, polar molecule, it is expected to be readily excreted. Specific PK data are not available in the literature.
|
| Toxicity/Toxicokinetics |
Potassium 2-hydroxy-2-methylsuccinate has a low toxicity profile as it is a naturally occurring endogenous metabolite. It is not considered a hazardous substance. For research use, standard laboratory safety practices are sufficient. Comprehensive toxicology studies have not been published for this compound.
|
| Additional Infomation |
Potassium 2-hydroxy-2-methylsuccinate is an endogenous metabolite used as a research reagent to explore metabolic pathways, enzyme interactions, and organic synthesis processes. It is also known as (±)-citramalic acid dipotassium salt monohydrate. The compound is not a drug and has no therapeutic indications. It is available for laboratory research use only.
|
| Molecular Formula |
C5H6K2O5
|
|---|---|
| Molecular Weight |
224.29
|
| Exact Mass |
223.948
|
| CAS # |
1030365-02-6
|
| PubChem CID |
16211775
|
| Appearance |
White to off-white solid powder
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
12
|
| Complexity |
152
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC(CC(=O)[O-])(C(=O)[O-])O.[K+].[K+]
|
| InChi Key |
VCJUJDUIBZISHE-UHFFFAOYSA-L
|
| InChi Code |
InChI=1S/C5H8O5.2K/c1-5(10,4(8)9)2-3(6)7;;/h10H,2H2,1H3,(H,6,7)(H,8,9);;/q;2*+1/p-2
|
| Chemical Name |
dipotassium;2-hydroxy-2-methylbutanedioate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O: 250 mg/mL (1114.63 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.4585 mL | 22.2926 mL | 44.5851 mL | |
| 5 mM | 0.8917 mL | 4.4585 mL | 8.9170 mL | |
| 10 mM | 0.4459 mL | 2.2293 mL | 4.4585 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
